✦ LIBER ✦

Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer

✍ Scribed by Diaz-Rubio, E.; Pietrantonio, F.; de Braud, F.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

XELOX and bevacizumab followed by single

✍ Rosati, Gerardo; Avallone, Antonio; Aprile, Giuseppe; Butera, Alfredo; Reggiardo 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 269 KB

PCN87 PHARMACOECONOMIC ANALYSIS OF DIREC

✍ A Tikhomirova; A Kulikov; R Yagudina 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

Commentary on a Phase III Trial of Bevac

✍ Preeta Tyagi; Axel Grothey 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 141 KB

Maintenance single-agent bevacizumab or

✍ Moscetti, Luca; Nelli, Fabrizio; Fabbri, Maria A; Sperduti, Isabella; Alesini, D 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 233 KB

Axitinib or Bevacizumab Plus FOLFIRI or

✍ Bendell, Johanna C.; Tournigand, Christophe; Swieboda-Sadlej, Anna; Barone, Carl 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 292 KB

Phase III Trial of FOLFOX plus Bevacizum

✍ Jane D. Robertson; Nick A. Botwood; Mace L. Rothenberg; Hans-Joachim Schmoll 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 77 KB